


703-787-1111



09000001ZA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

REVOCATION OF POWER OF ATTORNEY and
APPOINTMENT OF NEW POWER OF ATTORNEY

RECEIVED
APR 18 2005
TECH CENTER 1600/2900

I hereby revoke all previous powers of attorney given in the following applications and patents:

Patent Number: 5,466,675
Patent Number: 5,455,232
Patent Number: 5,514,661
Application No: 10/048,923
Application No: 09/644,984

Issued: November 15, 1995
Issued: October 3, 1995
Issued: May 7, 1996
Filed: ~~May 7, 1996~~ May 22, 2002
Filed: August 24, 2000

Inventor: G. Piljac et al.
Inventor: G. Piljac et al.
Inventor: G. Piljac et al.
Inventor: G. Piljac et al.
Inventor: G. Piljac et al.

☒ A power of Attorney is submitted herewith.

OR

☒ I hereby appoint the practitioners associated with the Customer Number: 30743☒ Please change the correspondence address for the above-identified patents and applications to:☒ The address associated with Customer Number: 30743

OR

☒ Firm Name

Whitham, Curtis & Christofferson, P.C.

Address

11491 Sunset Hills Road

Address

Suite 340

City

Reston

Country

USA

State

VA

ZIP

20190

Telephone

703-787-9400

Fax

703-787-7557

I am the:

☐ Applicant/Inventor☒ Assignee of the entire interest. An assignment recordation and accompanying assignment is concurrently submitted herewith.

SIGNATURE of Applicant or Assignee

Name

Keith L. DeSanto, President, Paradigm Biomedical, Inc.

Signature

Date 10/20/04

Telephone

703-242-8355



POWER OF ATTORNEY

September 14, 2004

PARADIGM BIOMEDICAL, INC. hereby authorizes the law firm of WHITHAM, CURTIS & CHRISTOFFERSON, P.C. to take such action as may be necessary or convenient, on behalf of PARADIGM BIOMEDICAL, to prosecute and maintain the patents and patent applications owned by PARADIGM BIOMEDICAL, including but not limited to filing papers and fees with the patent agencies of any country where a PARADIGM BIOMEDICAL patent or patent application is active or pending or can be made active or pending, retaining and discharging local counsel and other agents, obtaining authorizations in suitable form from inventors of PARADIGM BIOMEDICAL patents and patent applications, and to perform such other acts as may be necessary or convenient for the aforesaid purposes.

Keith DeSanto, President
for PARADIGM BIOMEDICAL, INC.

Date: SEPTEMBER 14 2004

COPY

09000001ZA



RECEIVED
APR 18 2005
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patents and applications of:

G. Piljac et al.

Patent 5,466,675 issued November 14, 1995

Patent 5,455,232 issued October 3, 1995

Patent 5,514,661 issued May 7, 1996

Application: 10/048,923 filed May 22, 2002

Application: 09/644,984 filed August 24, 2000

Commissioner of Patents
PO Box 1450
Alexandria, Virginia 22313-1450

SUBMISSION OF ASSIGNMENT

Sir:

Kindly record and return to the undersigned the attached assignment from Goran Piljac et al., to Paradigm Biomedical, Inc., for the above-identified patents and applications. A check in the amount of \$200.00 is attached to cover the recordation fee.

A Revocation of Power of Attorney and Appointment of New Power of Attorney is concurrently submitted herewith.

Please charge any deficiencies in payments and credit any overpayments to Attorney's deposit account no. 50-2041.

Respectfully submitted,

Clyde R Christofferson
Reg. No.: 34,136

Whitham, Curtis & Christofferson, P.C.
11491 Sunset Hills Road, Suite 340
Reston, Virginia 20190

Customer No.: 30743
Telephone: 703-787-9400

RECORDATION FORM COVER SHEET

U.S. DEPARTMENT OF COMMERCE

Patent and Trademark Office

PATENTS ONLY

Tab settings → → → ▼ ▼ ▼ ▼ ▼ ▼ ▼ ▼

To the Director of the United States Patent and Trademark Office: Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):

Goran Piljac
Visnja Piljac
Tamara Piljac Stipcevic
Tihana Piljac
Jasenska Piljac

2. Name and address of receiving party(ies):

Name: Paradigm Biomedical, Inc.

Internal Address: _____

Street Address: 524 West 23rd StreetCity: New York State: NY ZIP: 10011Additional name(s) & address(es) attached? ☐ Yes ☒ NoAdditional names(s) of conveying party(ies) ☒ Yes ☐ No

3. Nature of conveyance:

- ☒ Assignment ☐ Merger
☐ Security Agreement ☐ Change of Name
☐ Other _____

Execution Date: May 2004

4. Application number(s) or patent numbers(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

10/048,923 filed 09/644,984 filed
May 22, 2002 August 24, 2000

B. Patent No.(s)

5,466,675 issued 5,455,232 issued 5,514,661 issued
November 14, 1995 October 3, 1995 May 7, 1996Additional numbers attached? ☐ Yes ☒ No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Clyde R Christofferson, Esq.Internal Address: Whitham, Curtis & Christofferson, P.C.Street Address: 11491 Sunset Hills Road, Suite 340City: Reston State: VA ZIP: 201906. Total number of applications and patents involved: 57. Total fee (37 CFR 3.41):.....\$ 200.00

- ☒ Enclosed - Any excess or insufficiency should be credited or debited to deposit account
☐ Authorized to be charged to deposit account

8. Deposit account number:

50-2041 (Whitham, Curtis & Christofferson, P.C.)

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Clyde R Christofferson

Name of Person Signing

Signature

8

Date

Total number of pages including cover sheet, attachments, and document: 8

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services

Director of the United States Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450

TRANSFER AND ASSIGNMENT OF PATENTS, PATENT RIGHTS, AND OTHER INTELLECTUAL PROPERTY ASSETS

1. The parties to this Transfer And Assignment Of Patents, Patent Rights, And Other Intellectual Property Assets are:

Goran Piljac, PhD, DVM, MD
Visnja Piljac, PhD
Tamara Piljac Stipcevic, PhD
Tihana Piljac, BS
Jasenska Piljac, PhD
Ante Piljac, MD Abit

Tukanac-Vijenac A2/10
Zagreb, Croatia 10000;

and

Tatjana (Tanja) Piljac Dujmic, PhD, MD
34224 Colleen Terrace
Fremont, California 94555-3841;


and


TAJCO, Inc., a Virginia Corporation;


collectively referred to as "Property Holders,"


2. The effective date of this Agreement is 15 May 2004 notwithstanding the actual dates on which it was actually signed by the Property Holders.
3. On 7 November 2003, the Property Holders entered into an Option To Purchase Assets Agreement (Option Agreement) with Goldes Holdings, LLC (Goldes). On 4 February 2004, pursuant to the terms of that Option Agreement, Goldes exercised its option to purchase the assets of the Property Holders. Paradigm Biomedical, Inc., (Paradigm) the new company formed pursuant to that option agreement *albeit* with a name change from TADJCO Biomedical Research (USA), Inc., has, by resolution of the Board, caused the transfer of 20% of the ownership of Paradigm in the form of stock to the Property Holders and has made clear that the 20% ownership of the Property Holders cannot be diluted, as provided by the Option Agreement. Further, the compensation to Goran Piljac has been effectuated by email from the attorney for Paradigm to the attorney for Goran Piljac. It also appears that payment of all the patent fees and expenses as setout in the Option Agreement have been complied with. The purpose of this Transfer, therefore, is to effectuate the Property Holders' obligations under the Option Agreement.
4. For the consideration stated in paragraph 3, above, and stated in the Option Agreement, the Property Holders hereby transfer, convey, sell, and assign all rights, title, ownership, and interest to and in all patents, pending patents, discoveries, and associated technology, including all know-how, described in Attachment A to Paradigm Biomedical, Inc. It is acknowledged and agreed by


the Property Holders that it is possible that a patent or a pending patent and its associated technology is omitted from Attachment A because of a mistake. If a patent or pending patent and its associated technology is omitted from Attachment A by inadvertence and it should have been included in Attachment A within the meaning of the Option Agreement, it is the duty of the Property Holders to transfer and assign all such patents, patent rights, and associated technology to Paradigm by this transfer. Therefore, if any patent or pending patent and its associated technology are inadvertently omitted from Attachment A, Property Holders agree to cooperate and to sign any documents to effectuate the transfer of said property to Paradigm, including documents for recording the assignments and transfers of these rights to Patent offices around the world.


Goran Piljac
Zagreb, Croatia
Date 05/10/ 2004


Visnja Piljac
Zagreb, Croatia
Date May 10, 2004


Tatjana Piljac Dujmic
Fremont, CA
Date May 17 2004


Tamara Piljac Stipcevic
Zagreb, Croatia
Date May 10, 2004


Jasenka Piljac
Zagreb, Croatia
Date May 11 2004

Tihana Piljac

Tihana Piljac

Zagreb, Croatia

Date May 11, 2004

Ante Piljac

Ante Piljac

Zagreb, Croatia

Date May 10, 2004

TAJCO, Inc

Goran Piljac

By Goran Piljac,

President, TAJCO, Inc.

Date May 10 / 2004

Pj
1607

ATTACHMENT A

Piljac Patent Portfolio		
Last Revised 03/29/2004		
Country/Region	Title	Serial or Pat. No.
AU	Immunological Activity of Rhamnolipids	31266/95
CA	Immunological Activity of Rhamnolipids	<u>2195419</u>
EPG	Immunological Activity of Rhamnolipids	94927153.7
GB	Immunological Activity of Rhamnolipids	95927153.7
JP	Immunological Activity of Rhamnolipids	08-505141
US	Immunological Activity of Rhamnolipids	5466675
US	Immunological Activity of Rhamnolipids	5514661

Py
12/11

AU	Rhamnolipids in the Scarless Wound Healing, Burn Shock, Atherosclerosis, Rejection of Transplanted Organs, Depression and Schizophrenia	<u>747088</u>
CA	Rhamnolipids in the Scarless Wound Healing, Burn Shock, Atherosclerosis, Rejection of Transplanted Organs, Depression and Schizophrenia	<u>2321926</u>
EP	Rhamnolipids in the Scarless Wound Healing, Burn Shock, Atherosclerosis, Rejection of Transplanted Organs, Depression and Schizophrenia	99936031.6
JP	Rhamnolipids in the Scarless Wound Healing, Burn Shock, Atherosclerosis, Rejection of Transplanted Organs, Depression and Schizophrenia	2000-533130
US	Use of Rhamnolipids in Wound Healing, Treating Burn Shock, Atherosclerosis, Organ Transplants, Depression, Schizophrenia and Cosmetics	09/644,984



AU	Use of Rhamnolipids in Wound Healing, Treatment and Prevention of Gum Disease and Periodontal Regeneration	<u>64893/00</u>
CA	Use of Rhamnolipids in Wound Healing, Treatment and Prevention of Gum Disease and Periodontal Regeneration	<u>2378557</u>
EP	Use of Rhamnolipids in Wound Healing, Treatment and Prevention of Gum Disease and Periodontal Regeneration	952141
US	Use of Rhamnolipids in Wound Healing, Treatment and Prevention of Gum Disease and Periodontal Regeneration	10/048,923
US	Pharmaceutical Preparation Based on Rhamnolipid	5455232
JP	Pharmaceutical Preparation Based on Rhamnolipid	5-512946
JP	Pharmaceutical Preparation Based on Rhamnolipid	Divisional of 5-512946
CA	Pharmaceutical Preparation Based on Rhamnolipid	2129542
<u>BE</u>	Pharmaceutical Preparation Based on Rhamnolipid	<u>1005704</u>

PH

EP	Pharmaceutical Preparation Based on Rhamnolipid	Granted 93914523.1
----	---	-----------------------

In addition to the above patents, title and possession in the following are also included in this transfer to Paradigm by the Property Holders:

1. **Three (3) Strains** (species of actinomyces) that show novel treatment effects against AIDS in vitro and human cancers.
2. **One Strain** (a species of pseudomonas) that can be formulated to produce antibiotics active against all tested (45) antibiotic resistant staphylococcus aureus and staphylococcus epidermis.
3. **Approximately 10,490 strains** derived from natural sources. These strains have been freeze-dried and are stored and ready for additional research to discover possible compounds with novel effectiveness for treatment of diseases using knowledge gathered from the research heretofore done over the last 15 years.